213 results on '"Kimby, Eva"'
Search Results
2. Diversity of intratumoral regulatory T cells in B-cell non-Hodgkin lymphoma
3. Factors Affecting the Clinical Course of Follicular Lymphoma: A Multistate Survival Analysis Using Individual Patient Data from Eight Multicenter Randomized Clinical Trials
4. Genomic and microenvironmental landscape of stage I follicular lymphoma, compared with stage III/IV
5. Distinct clinical and genetic features of hepatitis B virus–associated follicular lymphoma in Chinese patients
6. Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials
7. Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials
8. Treatment sequencing and impact of number of treatment lines on survival in follicular lymphoma: A national population‐based study.
9. Absolute B cell counts in blood predict long-term response in follicular lymphoma patients treated with rituximab without chemotherapy
10. Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy
11. The role of BAFF and G-CSF for rituximab-induced late-onset neutropenia (LON) in lymphomas
12. High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies
13. Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis
14. Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia A randomized study by the Swedish CLL group
15. Safety and immunogenicity of inactivated varicella-zoster virus vaccine in adults with hematologic malignancies receiving treatment with anti-CD20 monoclonal antibodies
16. Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years
17. Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia
18. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial
19. Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone
20. Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?
21. Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus
22. Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma
23. Lack of reproducibility of histopathological features in MYC‐rearranged large B cell lymphoma using digital whole slide images: a study from the Lunenburg lymphoma biomarker consortium.
24. Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's Macroglobulinemia.
25. Health-related quality of life and chronic fatigue in long-term survivors of indolent lymphoma – a comparison with normative data.
26. Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma
27. High incidence of chronic graft-versus-host disease after myeloablative allogeneic stem cell transplantation for chronic lymphocytic leukemia in Sweden: graft-versus-leukemia effect protects against relapse
28. Lack of association between the MDM2 promoter polymorphism SNP309 and clinical outcome in chronic lymphocytic leukemia
29. Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia
30. TCL1A expression delineates biological and clinical variability in B-cell lymphoma
31. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo–purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group
32. Tumor burden status evaluated by computed tomography scan is of prognostic importance in patients with chronic lymphocytic leukemia
33. Late-onset neutropenia associated with rituximab therapy: evidence for a maturation arrest at the (pro)myelocyte stage of granulopoiesis
34. Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemia
35. Management of advanced-stage peripheral T-cell lymphomas
36. Signaling molecules and cytokine production in T cells of patients with B-cell chronic lymphocytic leukemia (B-CLL): Comparison of indolent and progressive disease
37. Posttransplant lymphoma—A single-center experience of 500 liver transplantations
38. ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)
39. Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop
40. Clinical characteristic and outcome of lymphoplasmacytic lymphoma of non‐Waldenstrom macroglobulinemia type: A Swedish lymphoma registry study.
41. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur
42. Better response with conjugate vaccine than with polysaccaride vaccine 12 months after rituximab treatment in lymphoma patients
43. Clinical significance of the WHO grades of follicular lymphoma in a population-based cohort of 505 patients with long follow-up times
44. Myeloablative allogeneic stem cell transplantation for lymphoblastic lymphoma in Sweden: A retrospective study
45. Safety analysis of ex vivo-expanded NK and NK-like T cells administered to cancer patients: a Phase I clinical study
46. Advances in the Biology and Treatment of Waldenström's Macroglobulinemia: A Report from the 5th International Workshop on Waldenström's Macroglobulinemia, Stockholm, Sweden
47. Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic leukaemia
48. Portal vein thrombosis is a common complication following splenectomy in patients with malignant haematological diseases
49. Update on Recommendations for Assessing Response from the Third International Workshop on Waldenströmʼs Macroglobulinemia
50. Pharmacogenetics of cyclophosphamide in patients with hematological malignancies
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.